Axogen Inc. (LT3)
XFRA 
Summary
LT3 Chart
Axogen: The Regulatory Moat Is Becoming A Commercial Flywheel
Axogen is transforming from a niche tissue supplier into a comprehensive nerve care platform, underpinned by FDA approval, stronger reimbursement, and expanding clinical evidence. Q2 2026 revenue grew 23.1% to $69.7M, with raised full-year guidance and strong elective market traction, though gross margin declined due to product mix and biologic costs. Avance's FDA biologic approval grants 12 years of exclusivity, regulatory credibility, and improved payer coverage, positioning AXGN as a category leader with significant market opportunity.
Axogen, Inc. (AXGN) Q2 2026 Earnings Call Transcript
Axogen, Inc. (AXGN) Q2 2026 Earnings Call Transcript
AxoGen Q2 Earnings Call Highlights
AxoGen NASDAQ: AXGN reported second-quarter 2026 revenue of $69.7 million, up 23.1% from a year earlier, as demand for its Avance nerve graft and broader product portfolio increased across its target markets. The company raised its full-year revenue outlook to at least $279 million, representing growth of at least 24%, while lowering its gross-margin expectation to at least 73% due to product-mix changes tied to faster-than-expected growth in breast reconstruction.
Axogen Inc. (LT3) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Axogen Inc. ever had a stock split?
Axogen Inc. Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Michael D. Dale CEO | XFRA Exchange | 05463X106 CUSIP |
| US Country | 622 Employees | 12 Feb 2010 Last Dividend | 11 Jul 1994 Last Split | 27 Mar 1990 IPO Date |
Overview
AxoGen, Inc., alongside its subsidiaries, plays a pivotal role in advancing the field of peripheral nerve regeneration and repair around the globe. This innovative company is focused on developing and bringing to market specialized technologies that address critical needs in nerve repair. By providing state-of-the-art solutions, AxoGen, Inc. is committed to improving the quality of life for patients suffering from peripheral nerve injuries. The company serves a diverse clientele, including hospitals, surgery centers, military hospitals, as well as plastic reconstructive, orthopedic, and hand surgeons, and oral and maxillofacial surgeons, operating out of its headquarters in Alachua, Florida.
Products and Services
-
Avance Nerve Graft
A pioneering product in nerve repair, the Avance Nerve Graft is a biologically active, off-the-shelf processed human nerve allograft designed for bridging severed peripheral nerves. This innovative solution offers a significant advantage by eliminating the comorbidities associated with harvesting grafts from a second surgical site, thereby facilitating a more efficient and less invasive recovery for patients.
-
AxoGuard Nerve Connector
This product takes advantage of a porcine submucosa extracellular matrix (ECM) to assist in the tensionless repair of severed peripheral nerves. The AxoGuard Nerve Connector facilitates the precise alignment and connection of nerve endings, promoting optimal healing and nerve function recovery.
-
AxoGuard Nerve Protector
As a porcine submucosa ECM product, the AxoGuard Nerve Protector is utilized to wrap and safeguard damaged peripheral nerves. It plays a vital role in nerve reconstruction by reinforcing the repair process while preventing soft tissue attachments, thereby ensuring the integrity and functionality of the nerve post-repair.
-
Axoguard HA+ Nerve Protector
This advanced version incorporates a processed porcine submucosa ECM base layer along with a hyaluronate-alginate gel coating. The Axoguard HA+ Nerve Protector is specifically designed to provide both short and long-term protection for peripheral nerve injuries, offering an enhanced barrier and healing environment.
-
Axoguard Nerve Cap
The Axoguard Nerve Cap is crafted from a porcine submucosa ECM and is used to protect the end of a peripheral nerve. It effectively isolates the nerve from the surrounding tissues to minimize the development of symptomatic or painful neuroma, thereby contributing to a better patient outcome.
-
AxoTouch Two-Point Discriminator
This specialized tool is employed for measuring the innervation density of the skin's surface area. The AxoTouch Two-Point Discriminator is an essential instrument for assessing the success of nerve repair and recovery, providing valuable feedback for surgeons and patients alike.
